Camilla Di Paolo

Camilla Di Paolo

SSVD Allergology, Di Brescia Civil Hospital, Civil Hospital p.le 1, Brescia
Italy

Publications
  • Case Report
    Cutaneous Adverse Reactions to Imatinib: A Case Report of a Successful Slow Protocol for Induction of Drug Tolerance
    Author(s): Camilla Di Paolo, Stefano Minetti, Michela Mineni, Silvia Inverardi, Fabio Lodi Rizzini, Massimo Cinquini and Cinzia Tosoni Camilla Di Paolo, Stefano Minetti, Michela Mineni, Silvia Inverardi, Fabio Lodi Rizzini, Massimo Cinquini and Cinzia Tosoni

    Imatinib mesylate (Gleevec®- Novartis, UK) is a selective tyrosine kinase inhibitor widely used for the treatment of hematologic diseases such as chronic myeloid leukemia (CML). Administration of Imatinib has been related to both cutaneous side effects and hypersensitivity reactions. Since it often is a unique therapeutic option for the treatment of CML, desensitization becomes an option in patients who develop hypersensitivity reactions and do not have equally effective therapeutic options. We hereby propose a possible slow protocol for induction of tolerance, suitable for patients who develop cutaneous delayed reactions. .. View More»
    DOI: 10.4172/2155-6121.1000203

    Abstract PDF